Rationale: "Noninfectious" pulmonary complications are significant causes of morbidity and mortality after allogeneic hematopoietic cell transplant. Early-onset viral reactivations or infections are common after transplant. Whether the first-onset viral infection causes noninfectious pulmonary complications is unknown. Objectives: To determine whether the first-onset viral infection within 100 days after transplant predisposes to development of noninfectious pulmonary complications. Methods: We performed a retrospective review of 738 allogeneic hematopoietic cell transplant patients enrolled from 2005 to 2011. We also established a novel bone marrow transplantation mouse model to test whether herpesviral reactivation after transplant causes organ injury. Measurements and Main Results: First-onset viral infections with human herpesvirus 6 or Epstein-Barr virus within 100 days after transplant increase the risk of developing idiopathic pneumonia syndrome (adjusted hazard ratio [aHR], 5.52; 95% confidence interval [CI], 1.61-18.96; P = 0.007; and aHR, 9.21; 95% CI, 2.63-32.18; P = 0.001, respectively). First infection with human cytomegalovirus increases risk of bronchiolitis obliterans syndrome (aHR, 2.88; 95% CI, 1.50-5.55; P = 0.002) and grade II-IV acute graft-versus-host disease (aHR, 1.59; 95% CI, 1.06-2.39; P = 0.02). Murine roseolovirus, a homolog of human herpesvirus 6, can also be reactivated in the lung and other organs after bone marrow transplantation. Reactivation of murine roseolovirus induced an idiopathic pneumonia syndrome-like phenotype and aggravated acute graft-versus-host disease. Conclusions: First-onset herpesviral infection within 100 days after allogeneic hematopoietic cell transplant increases risk of pulmonary complications. Experimentally reactivating murine roseolovirus causes organ injury similar to phenotypes seen in human transplant recipients.
Rationale: "Noninfectious" pulmonary complications are significant causes of morbidity and mortality after allogeneic hematopoietic cell transplant. Early-onset viral reactivations or infections are common after transplant. Whether the first-onset viral infection causes noninfectious pulmonary complications is unknown. Objectives: To determine whether the first-onset viral infection within 100 days after transplant predisposes to development of noninfectious pulmonary complications. Methods: We performed a retrospective review of 738 allogeneic hematopoietic cell transplant patients enrolled from 2005 to 2011. We also established a novel bone marrow transplantation mouse model to test whether herpesviral reactivation after transplant causes organ injury. Measurements and Main Results: First-onset viral infections with human herpesvirus 6 or Epstein-Barr virus within 100 days after transplant increase the risk of developing idiopathic pneumonia syndrome (adjusted hazard ratio [aHR], 5.52; 95% confidence interval [CI], 1.61-18.96; P = 0.007; and aHR, 9.21; 95% CI, 2.63-32.18; P = 0.001, respectively). First infection with human cytomegalovirus increases risk of bronchiolitis obliterans syndrome (aHR, 2.88; 95% CI, 1.50-5.55; P = 0.002) and grade II-IV acute graft-versus-host disease (aHR, 1.59; 95% CI, 1.06-2.39; P = 0.02). Murine roseolovirus, a homolog of human herpesvirus 6, can also be reactivated in the lung and other organs after bone marrow transplantation. Reactivation of murine roseolovirus induced an idiopathic pneumonia syndrome-like phenotype and aggravated acute graft-versus-host disease. Conclusions: First-onset herpesviral infection within 100 days after allogeneic hematopoietic cell transplant increases risk of pulmonary complications. Experimentally reactivating murine roseolovirus causes organ injury similar to phenotypes seen in human transplant recipients.
Authors: Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers Journal: Biol Blood Marrow Transplant Date: 2014-12-18 Impact factor: 5.742
Authors: H Einsele; H Hebart; C Kauffmann-Schneider; C Sinzger; G Jahn; P Bader; T Klingebiel; K Dietz; J Löffler; C Bokemeyer; C A Müller; L Kanz Journal: Bone Marrow Transplant Date: 2000-04 Impact factor: 5.483
Authors: Danielle M Zerr; Lawrence Corey; Hyung W Kim; Meei-Li Huang; Long Nguy; Michael Boeckh Journal: Clin Infect Dis Date: 2005-03-02 Impact factor: 9.079
Authors: Swapneel J Patel; Guoyan Zhao; Vinay R Penna; Eugene Park; Elvin J Lauron; Ian B Harvey; Wandy L Beatty; Beatrice Plougastel-Douglas; Jennifer Poursine-Laurent; Daved H Fremont; David Wang; Wayne M Yokoyama Journal: J Virol Date: 2017-04-13 Impact factor: 5.103
Authors: Michael J Carlson; Michelle L West; James M Coghill; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody Journal: Blood Date: 2008-10-28 Impact factor: 22.113
Authors: Pierre Teira; Minoo Battiwalla; Muthalagu Ramanathan; A John Barrett; Kwang Woo Ahn; Min Chen; Jaime S Green; Ayman Saad; Joseph H Antin; Bipin N Savani; Hillard M Lazarus; Matthew Seftel; Wael Saber; David Marks; Mahmoud Aljurf; Maxim Norkin; John R Wingard; Caroline A Lindemans; Michael Boeckh; Marcie L Riches; Jeffery J Auletta Journal: Blood Date: 2016-02-16 Impact factor: 22.113
Authors: Joshua A Hill; W Garrett Nichols; Francisco M Marty; Genovefa A Papanicolaou; Thomas M Brundage; Randall Lanier; Danielle M Zerr; Michael J Boeckh Journal: Blood Date: 2020-04-23 Impact factor: 22.113
Authors: Robert F Tamburro; Kenneth R Cooke; Stella M Davies; Samuel Goldfarb; James S Hagood; Ashok Srinivasan; Marie E Steiner; Dennis Stokes; Nancy DiFronzo; Nahed El-Kassar; Nonniekaye Shelburne; Aruna Natarajan Journal: Ann Am Thorac Soc Date: 2021-03
Authors: David S Wenger; Matthew Triplette; Kristina Crothers; Guang-Shing Cheng; Joshua A Hill; Filippo Milano; Shahida Shahrir; Gary Schoch; Lisa K Vande Vusse Journal: Biol Blood Marrow Transplant Date: 2019-10-09 Impact factor: 5.742